Enanta Pharma Files 8-K on Financial Results & Operations
Ticker: ENTA · Form: 8-K · Filed: Feb 7, 2024 · CIK: 1177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K, financial-statements
TL;DR
**Enanta just dropped an 8-K with financial results, time to check their numbers!**
AI Summary
Enanta Pharmaceuticals, Inc. filed an 8-K on February 7, 2024, to report on its 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits.' This filing, under SEC File Number 001-35839, indicates that the company is providing an update on its financial performance. For investors, this matters because it offers a timely snapshot of Enanta's financial health, which can influence stock valuation and future investment decisions.
Why It Matters
This filing provides investors with crucial, up-to-date financial information about Enanta Pharmaceuticals, Inc., enabling them to assess the company's performance and make informed investment decisions.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information, not indicating any immediate new risks or significant changes.
Analyst Insight
A smart investor would review the detailed financial statements and results of operations that accompany this 8-K to understand Enanta's current financial health and performance trends before making any investment decisions.
Key Numbers
- 001-35839 — SEC File Number (identifies Enanta's registration with the SEC)
- 02472 — Zip Code (part of Enanta's principal executive offices address)
- 617 607 0800 — Business Phone Number (contact information for Enanta Pharmaceuticals, Inc.)
- $0.01 — par value per share (the par value of Enanta's Common Stock)
Key Players & Entities
- ENANTA PHARMACEUTICALS INC (company) — the registrant filing the 8-K
- February 07, 2024 (date) — the date of the earliest event reported and filing date
- 001-35839 (dollar_amount) — the SEC File Number for the registrant
- 500 Arsenal Street, Watertown, Massachusetts, 02472 (company) — the business address of Enanta Pharmaceuticals, Inc.
- Nasdaq Global Select Market (company) — the exchange where Enanta's Common Stock is registered
FAQ
What is the primary purpose of this 8-K filing by Enanta Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing, dated February 7, 2024, is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as per Item 2.02 and Item 9.01 of Form 8-K.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was February 07, 2024.
What is the trading symbol and the exchange where Enanta Pharmaceuticals, Inc.'s Common Stock is registered?
Enanta Pharmaceuticals, Inc.'s Common Stock trades under the symbol 'ENTA' and is registered on the Nasdaq Global Select Market.
What is the state of incorporation for Enanta Pharmaceuticals, Inc.?
Enanta Pharmaceuticals, Inc. is incorporated in Delaware.
Is Enanta Pharmaceuticals, Inc. considered an emerging growth company according to this filing?
No, the filing indicates with a checkbox that Enanta Pharmaceuticals, Inc. is not an emerging growth company.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 11.6 · Accepted 2024-02-07 16:05:12
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select
Filing Documents
- enta-20240207.htm (8-K) — 36KB
- enta-ex99_1.htm (EX-99.1) — 160KB
- img152620751_0.jpg (GRAPHIC) — 16KB
- 0000950170-24-012186.txt ( ) — 340KB
- enta-20240207.xsd (EX-101.SCH) — 24KB
- enta-20240207_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 7, 2024, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended December 31, 2023. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release of Enanta Pharmaceuticals, Inc. dated February 7, 2024, reporting Enanta's financial results for the fiscal quarter ended December 31, 2023 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ENANTA PHARMACEUTICALS, INC. Date: February 7, 2024 By: /s/ Paul J. Mellett Paul J. Mellett Chief Financial and Administrative Officer